Envision Report

Published January 11, 2018

Novel Drug Delivery Systems Market – Size, Outlook, Trends and Forecasts (2018 – 2024)

Request Free Sample Report!

Novel drug delivery system (NDDS) provides a therapeutic amount of drug to the specific site in the body to accomplish promptly and then maintain the desired drug concentration. The drug- delivery system should deliver drug at a rate control by the necessity of the body over a specified term of treatment. The novel drug delivery technologies enable to formulate the novel drug delivery devices by incorporating the drug molecules into new delivery systems, thus providing numerous therapeutic and commercial advantages.

Novel Drug Delivery Systems(NDDS) Market Segments Size & Growth:

Biopharmaceuticals market size is projected to reach approximately $294 billion by the end of 2024 with a CAGR of close to 8.9% from $178 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Increase in individual therapy, Requirement of controlled release of drugs, Increasing understanding of drug metabolism per individual and so on. However, Competition, Product Recalls, Stringent Regulatory Guidelines, Stability issues are thereby hampering the market growth.

Novel Drug Delivery Systems(NDDS) Market Segments Share:

Novel drug delivery systems(NDDS) market is categorised into Route of Administration which comprises of Transdermal drug delivery systems, Pulmonary drug delivery systems, Injectable drug delivery systems, Oral drug delivery systems and so on. Among the Route of Administration, Injectable drug delivery systems segment dominated the Biopharmaceuticals market in 2018. On the basis of Geography, North America is projected to eclipse the Novel drug delivery systems(NDDS) market and the growth in the North America economies is mainly attributed because of high disposable income, increasing research and development activities associated with development of drug delivery systems, high adoption rate of novel technologies and supportive reimbursement policies.

Novel Drug Delivery Systems(NDDS) Market Trends:

  • GlaxoSmithKline and Chroma Therapeutics Limited announced a collaboration to develop Novel macrophage-targeted compounds using Chroma’s proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targeting the compounds to specific cells in the inflammatory disease process.
  • Sanofi and Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimise development and commercialisation of specific products for the treatment of rare genetic diseases. Specifically:

Novel Drug Delivery Systems(NDDS) Market Research Report:

  • An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
  • To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
  • Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
  • Identifying DROC in the current market and their impact in altering the market dynamics.
  • Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
  • Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
  • The primary market players, such as
  • Genzyme Corporation
  • GlaxoSmithKline PLC
  • Generex Biotechnology Corporation
  • Genentech Inc.
  • Johnson & Johnson

Chapter 1 Introduction

1.1 Executive Summary

1.2 Market Definition

1.3 Scope of  the Study

Chapter 2 Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.3 Analytic Tools and Model

2.4 Economic Indicator

2.4.1 Base Year, Base Currency, Forecasting Period

2.5 Expert Validation

2.6 Study Timeline

Chapter 3 Market Analysis

3.1 Industry Value Chain Analysis

3.2 Porter’s Five Analysis

3.2.1 Bargaining Power of Buyers

3.2.2 Bargaining Power of Suppliers

3.2.3 Threats of Substitutes

3.2.4 Threats of New Entrants

3.2.5 Industry Rivalry

3.3 PESTLE Analysis

3.3.1 Political

3.3.2 Economical

3.3.3 Social

3.3.4 Technological

3.3.5 Legal

3.3.6 Environmental

3.4 SWOT Analysis

3.4.1 Strengths

3.4.2 Weakness

3.4.3 Opportunities

3.4.4 Threat

3.5 Y-O-Y Analyses

Chapter 4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

Chapter 5 Market Segmentation Analysis        

Chapter 6 Market Segmentation, By Route of Administration 

     6.1 Transdermal Drug Delivery Systems

6.2 Pulmonary Drug Delivery Systems

6.3 Injectable Drug Delivery Systems

6.4 Oral Drug Delivery Systems

Chapter 7 Market Segmentation, By Geography

7.1 North America

7.1.1 Introduction

7.1.2 United States

7.1.3 Canada

7.1.4 Mexico

7.1.5 Others

7.2 Europe

7.2.1 Introduction

7.2.2 U.K

7.2.3 Spain

7.2.4 Italy

7.2.5 France

7.2.6 Russia

7.2.7 Others

7.3 Asia-Pacific

7.3.1 Introduction

7.3.2 China

7.3.3 India

7.3.4 Japan

7.3.5 Australia & New Zealand

7.3.6 Others

7.4 South  America

7.4.1 Introduction

7.4.2 Brazil

7.4.3 Argentina

7.4.4 Others

7.5 The Middle East & Africa

7.5.1 Introduction

7.5.2 South Africa

7.5.3 Others

Chapter 8 Competitive Landscape

8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements

8.2  Market Share Analysis

8.3 Strategies Adopted By Top Companies

Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

9.1. Genzyme Corporation

9.1.1. Company Overview

9.1.2. Financial Performance

9.1.3. Product Benchmarking

9.1.4. Strategic Initiative

9.2. Generex Biotechnology Corporation

9.3. Genentech Inc.

9.4. Cephalon, Inc.

9.5. Celgene Corporation

9.6. Bristol-Myers Squibb

9.7. Boston Scientific

9.8. Boehringer Ingelheim

9.9. Bayer Healthcare Pharmaceuticals

9.10. Baxter International Inc.

9.11. Bausch & Lomb

9.12. AstraZeneca PLC

9.13. Amgen Inc.

9.14. Abbott Laboratories

9.15. 3M Company

Chapter 11 Market Estimates and Forecast

11.1   Market Estimates and Forecast 2018-2024(USD Million)

11.1.1 Market Estimation and Forecast by Route of Administration 2018-2024 (USD Million)

11.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)

Chapter 12 Market Insights

12.1 Insights of Industry Experts

13.2 Analyst Opinion (Market Understanding)

13.3 Investment Opportunities

Chapter 14 Appendix

14.1 List of Tables

14.2 List of Figures

  • Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
  • Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
  • The Regional and Global Variety is taken care of in the report.
  • Year on Year basis generation of revenue is studied.
  • Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
  • The overview and the sustainability of the market are analyzed through SWOT.
  • DROC is recognized in the current market scenario and see how its effect on market dynamics.
  • The segment-level analysis in terms of type and technology.
  • The value chain analysis, value that's created and captured by a company is the profit margin.Value
  • Created and Captured – Cost of Creating that Value = Margin
  • An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
  • Basis on the depth of the study we approach using analytical tools
  • Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.

 

©2018 - Envision Inteligence | All Rights Reserved.